PF-219,061 is a drug that was under development by Pfizer which acts as a potent and highly selective agonist for the dopamine D3 receptor.[1][2] It was under development as a potential medication for the treatment of female sexual dysfunction.[3][4] It did not advance into clinical trials.[5]
Clinical data | |
---|---|
Routes of administration | Nasal |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C13H19NO2 |
Molar mass | 221.300 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |